Regeneron's Dupixent and Eylea Offset Drop in COVID-19 Antibody Sales

Regeneron Pharmaceuticals reported a 44% drop in revenue for the second quarter compared to the same period in 2021.

This overall drop was associated with sales of REGEN-COV, its antibody cocktail against COVID-19, banned in the U.S. in January, with a few exceptions, because it was ineffective against the Omicron variants. Otherwise, company sales were up 20%.